Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products

April 20, 2026 at 09:58 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

2149611199 1 1 Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products

The Company’s Health Canada-licensed GMP psychedelic manufacturing platform ready to serve emerging demand for ibogaine, a naturally occurring alkaloid under investigation for opioid use disorder, PTSD, and traumatic brain injury Vancouver, British Columbia–(April 20, 2026) – Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FSE: 8BN) (the “Company” or “Optimi“), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug … Continue reading

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol	Price	Change (%)
AMZN	246.02	+7.47 (3.13%)
AAPL	296.42	+5.29 (1.82%)
AMD	547.26	+35.69 (6.98%)
BAC	55.87	-0.15 (-0.27%)
GOOG	367.11	+8.95 (2.50%)
META	593.48	+26.50 (4.67%)
MSFT	399.76	+9.02 (2.31%)
NVDA	212.45	+7.26 (3.54%)
ORCL	192.64	+8.51 (4.62%)
TSLA	411.15	+4.72 (1.16%)

Symbol

Price

Change (%)

AMZN

246.02

+7.47 (3.13%)

AAPL

296.42

+5.29 (1.82%)

AMD

547.26

+35.69 (6.98%)

BAC

55.87

-0.15 (-0.27%)

GOOG

367.11

+8.95 (2.50%)

Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products

More News

Recent Quotes

Sections

Services

Contact Information

Follow Us